Brief: Tcr² Therapeutics Presents Preclinical Data On Il-15 Enhanced Trucs At Aacr Virtual Special Conference On Tumor Immunology & Immunotherapy
05/10/2021 14:37
Oct 5 (Reuters) - TCR2 Therapeutics Inc TCRR.O :
* TCR² THERAPEUTICS PRESENTS PRECLINICAL DATA ON IL-15
ENHANCED
TRUCS AT AACR VIRTUAL SPECIAL CONFERENCE ON TUMOR IMMUNOLOGY &
IMMUNOTHERAPY
* TCR2 THERAPEUTICS - ADMINISTRATION OF SINGLE DOSE OF IL-15
ENHANCED TRUC-T CELLS CLEARED TUMORS IN ALL MICE, PROTECTED THEM
FROM TUMOR RECHALLENGE
Source text for Eikon: ID:nGNX85tx5
Further company coverage: TCRR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TCR2 Therapeutics
See all newsBrief: TCR2 Therapeutics Entered Into An Assignment Of Lease Agreement With Astrazeneca
TCR2 Therapeutics falls on bigger-than-expected Q1 loss
Brief: Tcr² Therapeutics Reports Q1 2023 Financial Results And Provides Corporate Update
TCR2 Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
TCR2 Therapeutics Inc expected to post a loss of 68 cents a share - Earnings Preview